Organic compounds

IMBRUVICA® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukemia

Saturday, December 7, 2019 - 12:35pm

During this extended follow-up, IMBRUVICA was tolerated across all lines of therapy with 19 percent of patients discontinuing due to adverse events.

Key Points: 
  • During this extended follow-up, IMBRUVICA was tolerated across all lines of therapy with 19 percent of patients discontinuing due to adverse events.
  • These new findings from the E1912, RESONATE/RESONATE-2 and CAPTIVATE studieswere presented at the 2019 American Society of Hematology (ASH) Annual Meeting.
  • OS benefit also continued to favor the IMBRUVICA plus rituximab arm (HR, 0.34; 95 percent CI, 0.15-0.79; p=0.009).
  • The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.

IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

Saturday, December 7, 2019 - 12:30pm

In patients with uMRD in PB with matched BM samples, 93 percent of patients had uMRD in both PB and BM.

Key Points: 
  • In patients with uMRD in PB with matched BM samples, 93 percent of patients had uMRD in both PB and BM.
  • AEs leading to dose reductions occurred in 20 percent of patients overall (IMBRUVICA: 14 percent; VENCLEXTA/VENCLYXTO: 9 percent).
  • AEs leading to discontinuation were infrequent, occurring in 5 percent of patients overall (IMBRUVICA: 6 percent; VENCLEXTA/VENCLYXTO: 4 percent).
  • Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CAPTIVATE).https://clinicaltrials.gov/ct2/show/NCT02910583.

Data from Investigator-Sponsored Phase 2 Study of Calithera’s Telaglenastat with Azacitidine in Myelodysplastic Syndrome to be Presented at ASH Annual Meeting 2019

Friday, December 6, 2019 - 12:05pm

Date: Monday, December 9 at 7:30 a.m. Eastern Time

Key Points: 
  • Date: Monday, December 9 at 7:30 a.m. Eastern Time
    Telaglenastat is an investigational first-in-class glutaminase inhibitor specifically designed to block glutamine consumption in tumor cells.
  • Additional meeting information and accepted abstracts can be found at the ASH website www.hematology.org.
  • This investigator-sponsored trial is a single arm Phase 1b/2 trial of telaglenastat in combination with azacitidine for intermediate and high-risk MDS.
  • The primary outcome was to confirm the safety and recommended dose of telaglenastat in combination with azacitidine.

Curis Announces Positive Safety, Tolerability and Pharmacokinetic Data in Ongoing Phase 1 Study of Fimepinostat in Combination with Venetoclax

Friday, December 6, 2019 - 12:00pm

"We are very pleased with the progress in our ongoing Phase 1 study, with the combination of fimepinostat and venetoclax demonstrating a favorable tolerability profile thus far," said James Dentzer, President and Chief Executive Officer of Curis.

Key Points: 
  • "We are very pleased with the progress in our ongoing Phase 1 study, with the combination of fimepinostat and venetoclax demonstrating a favorable tolerability profile thus far," said James Dentzer, President and Chief Executive Officer of Curis.
  • "We believe fimepinostat is unique in its ability to target MYC through simultaneous inhibition of both PI3K and HDAC.
  • Curis' ongoing Phase 1, open-label, multi-center, dose-finding 3+3 study is designed to evaluate the safety and tolerability, PK and pharmacodynamics, and preliminary activity of the fimepinostat and venetoclax combination in patients with DLBCL, including those with DH/DE lymphoma.
  • Patients are enrolled in two cohorts in the study, with fimepinostat administered on a 5-days-on-2-days-off schedule in combination with venetoclax in 21-day cycles.

Antares Pharma Social Media Campaign for XYOSTED® Wins MarCom Platinum Award

Friday, December 6, 2019 - 12:00pm

EWING, N.J., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (Antares) (the Company) today announced that the Companys social media campaign for XYOSTED, has been honored with a 2019 MarCom Platinum Award.

Key Points: 
  • EWING, N.J., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (Antares) (the Company) today announced that the Companys social media campaign for XYOSTED, has been honored with a 2019 MarCom Platinum Award.
  • The social media campaign for XYOSTED featured a series of Facebook and Instagram ads to prime existing testosterone deficient patients for the launch of a new testosterone replacement therapy.
  • The social media campaign competed with other lifestyle content on the social platforms, with results that exceeded initial expectations.
  • We are honored to be recognized by the Association of Marketing and Communication Professionals with such a prestigious award for our XYOSTED social media campaign.

Medicure Announces Settlement of Holdback Dispute from Apicore Sale

Thursday, December 5, 2019 - 11:00pm

WINNIPEG, Dec. 5, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announced that it has reached a settlement agreement with the purchaser of Medicure's interests in Apicore with respect to the amounts heldback under the Apicore sale agreement.

Key Points: 
  • WINNIPEG, Dec. 5, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announced that it has reached a settlement agreement with the purchaser of Medicure's interests in Apicore with respect to the amounts heldback under the Apicore sale agreement.
  • A settlement agreement was reached under which Medicure will receive a net payment of US$5.1 million in relation to the holdback.
  • Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market.
  • The present focus of the Company is the marketing and distribution of AGGRASTAT(tirofiban hydrochloride) injection, ZYPITAMAGTM (pitavastatin) tablets and the ReDS device in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. For more information on Medicure please visit www.medicure.com .

Spartan Bioscience and Angiocare Partner to Bring the World's First Rapid Precision Medicine DNA Test to Cardiac Stent Patients in Europe

Thursday, December 5, 2019 - 7:00pm

(5) For heart attack patients, most complications from poor Plavix response occur in the first 24-48 hours after cardiac stenting.

Key Points: 
  • (5) For heart attack patients, most complications from poor Plavix response occur in the first 24-48 hours after cardiac stenting.
  • (6,7) Spartan's rapid, portable test allows real-time, near patient determination of the patient's genotype, aiding in determining the appropriate antiplatelet treatment.
  • and CEO of Spartan Bioscience, said, "We are looking forward to our partnership with Angiocare.
  • The Spartan logo is a registered trademark of Spartan Bioscience Inc.
    Plavix is a registered trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals.

Algernon Pharmaceuticals’ NP-120 (Ifenprodil) Outperforms Merck’s Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110%

Thursday, December 5, 2019 - 11:00am

Pharmidex, a contract research organization (CRO) and a global leader in respiratory research conducted the in-vivo cough study using the guinea pig citric acid challenge model.

Key Points: 
  • Pharmidex, a contract research organization (CRO) and a global leader in respiratory research conducted the in-vivo cough study using the guinea pig citric acid challenge model.
  • Note: Bellus Health Inc. has reported that BLU-5937 had comparable efficacy to Mercks MK-7264 (Gefapixant) in a guinea pig cough inhibition study that they conducted.
  • The Company previously reported that Ifenprodil was anti-fibrotic in a bleomycin mouse model of IPF, outperforming both Pirfenidone and Nintedanib.
  • Ifenprodil, an approved NMDA Glu2B subunit inhibitor, represents a potential novel first-in-class treatment for both chronic cough and IPF.

The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay

Thursday, December 5, 2019 - 11:00am

The LeukoStrat CDx FLT3 Mutation Assay may now be used as an aid in the assessment of AML patients for treatment with XOSPATA (gilteritinib) in Europe.

Key Points: 
  • The LeukoStrat CDx FLT3 Mutation Assay may now be used as an aid in the assessment of AML patients for treatment with XOSPATA (gilteritinib) in Europe.
  • FLT3 mutation must be confirmed with a validated test, such as the LeukoStrat CDx FLT3 Mutation Assay, which served as the companion diagnostic in the Phase 3 ADMIRAL trial resulting in approval of XOSPATA.
  • Companion diagnostics play a key role in the development and approval of targeted drug therapies.
  • Accordingly, the successful approval of a targeted therapy is highly dependent on the performance of the companion diagnostic.

Global Polyester Straps Market 2019-2023 | 15% CAGR Projection Over the Next Five Years | Technavio

Thursday, December 5, 2019 - 3:30am

The polyester straps market size is expected to post a CAGR of over 15% during the period 2019-2023, according to the latest market research report by Technavio.

Key Points: 
  • The polyester straps market size is expected to post a CAGR of over 15% during the period 2019-2023, according to the latest market research report by Technavio.
  • View the full release here: https://www.businesswire.com/news/home/20191204005709/en/
    Technavio has announced its latest market research report titled global polyester straps market 2019-2023.
  • This is mainly because polyester straps are lightweight and resistant to corrosion, and they ensure safe transportation and storage.
  • The APAC region led the polyester straps market in 2018, followed by North America, Europe, South America, and MEA respectively.